Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Strategy’s Near-$80 Billion Bitcoin Treasury Could Approach Cash Holdings of Amazon, Google and Microsoft

Strategy’s Near-$80 Billion Bitcoin Treasury Could Approach Cash Holdings of Amazon, Google and Microsoft

CoinotagCoinotag2025/10/08 02:54
By:Jocelyn Blake

  • Strategy holds 640,031 BTC (~$80B at peak):

  • Its BTC stash briefly approached the cash positions of Amazon, Google and Microsoft (each ~ $95–97B).

  • Strategy’s average buy price was $73,981, delivering roughly a 65% unrealized gain (~$30.4B).

Strategy Bitcoin treasury: 640,031 BTC (~$80B peak) challenges tech cash piles — read how corporate Bitcoin adoption is reshaping treasuries. Learn more.

What is Strategy’s Bitcoin treasury and how large is it?

Strategy’s Bitcoin treasury is a corporate reserve composed of 640,031 BTC purchased at an average price of $73,981. At Bitcoin’s recent record high near $126,080 the stash briefly topped $80 billion in market value, elevating Strategy into the top tier of corporate treasury valuations.

Strategy’s approach combines regular purchases with long-term holding, creating a prominent BTC-based component of its corporate balance sheet.

Strategy’s Near-$80 Billion Bitcoin Treasury Could Approach Cash Holdings of Amazon, Google and Microsoft image 0 Source: Strategy

How does Strategy’s Bitcoin stash compare to major tech cash positions?

Strategy’s Bitcoin value, near $80 billion at peak, sits close to the cash or cash-equivalent holdings reported by Amazon, Google and Microsoft (each roughly $95–97 billion). Berkshire Hathaway remains the largest corporate cash holder at about $344 billion.

Tesla also appears among top corporate treasuries and holds 11,509 BTC, worth roughly $1.4 billion — a small share of its overall cash position (~$37 billion).

Why did Microsoft and Meta reject Bitcoin proposals?

Microsoft and Meta shareholders voted against proposals to explore Bitcoin as a treasury asset primarily due to concerns about volatility and risk management. The proposals were submitted by a conservative think tank representative advocating for Bitcoin as a hedge against currency debasement.

Decision factors cited by shareholders included price volatility, regulatory uncertainty, and fiduciary duty to protect short-term capital.

When did corporate Bitcoin adoption accelerate in 2025?

Corporate Bitcoin adoption surged in 2025, with over 200 public companies holding BTC — up from fewer than 100 at the start of the year. Rising prices and institutional familiarity drove many firms to adopt or increase allocations to Bitcoin.

Strategy’s purchases have been a major driver of market attention, with its average buy price and subsequent unrealized gain frequently reported in corporate finance updates.


Frequently Asked Questions

How much gain has Strategy realized on its Bitcoin holdings?

Strategy’s average purchase price was $73,981 per BTC. With Bitcoin trading near recent highs, the position shows about a 65% unrealized gain — approximately $30.4 billion in market uplift.

What risks do companies cite when rejecting Bitcoin for treasuries?

Shareholder concerns commonly include high volatility, regulatory uncertainty, accounting treatment, and potential fiduciary risks tied to short-term valuation swings.

Key Takeaways

  • Scale: Strategy’s 640,031 BTC briefly reached ~ $80B, rivaling large tech cash positions.
  • Performance: Average buy price of $73,981 implies ~65% unrealized gains on the position.
  • Adoption trend: Corporate Bitcoin holdings expanded rapidly in 2025, with 200+ public companies holding BTC.

Conclusion

Strategy’s Bitcoin treasury has emerged as one of the largest corporate Bitcoin reserves, bringing BTC into direct comparison with major tech cash piles. As corporate adoption grows, the debate over Bitcoin’s role as an inflation hedge and treasury asset will continue to shape boardroom and shareholder decisions. For treasury teams, measured governance and robust risk controls remain essential.





Published by COINOTAG — Published: 2025-10-08 — Updated: 2025-10-08

In Case You Missed It: Cynthia Lummis Says U.S. Strategic Bitcoin Reserve Fundraising Could Start Anytime Despite Legislative Slog
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"

Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.

华尔街见闻•2026/09/29 01:01

Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business

Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.

华尔街见闻•2026/09/29 00:51

AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose

This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.

华尔街见闻•2026/09/29 00:26